Gary Nachman
Stock Analyst at Canaccord Genuity
(3.70)
# 751
Out of 5,241 analysts
109
Total ratings
60%
Success rate
4.68%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics | Maintains: Buy | $21 → $18 | $8.38 | +114.80% | 2 | May 7, 2026 | |
| ABBV AbbVie | Maintains: Buy | $262 → $265 | $209.41 | +26.55% | 19 | Apr 30, 2026 | |
| SRRK Scholar Rock Holding | Initiates: Buy | $62 | $47.38 | +30.86% | 6 | Apr 21, 2026 | |
| IONS Ionis Pharmaceuticals | Initiates: Buy | $110 | $72.52 | +51.68% | 5 | Apr 21, 2026 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $13 | $4.77 | +172.54% | 2 | Apr 21, 2026 | |
| AMGN Amgen | Initiates: Hold | $366 | $324.39 | +12.83% | 3 | Apr 21, 2026 | |
| BLCO Bausch + Lomb | Reiterates: Outperform | $18 → $19 | $16.11 | +17.94% | 2 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $6.90 | +624.64% | 3 | Oct 20, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $2.12 | +843.40% | 2 | Aug 13, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $12.05 | +132.37% | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $298 | $286.27 | +4.10% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $37 | $22.44 | +64.88% | 13 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $4.14 | +69.29% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $229.55 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $11.92 | -66.44% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $11.39 | +163.39% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $4.16 | +669.23% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $16.50 | -15.15% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $75 | $9.60 | +681.25% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $34.03 | -70.61% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $28.61 | +4.86% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $4.73 | +15,756.24% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $5.34 | +49.81% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $17.20 | +22.09% | 5 | May 11, 2020 |
ADMA Biologics
May 7, 2026
Maintains: Buy
Price Target: $21 → $18
Current: $8.38
Upside: +114.80%
AbbVie
Apr 30, 2026
Maintains: Buy
Price Target: $262 → $265
Current: $209.41
Upside: +26.55%
Scholar Rock Holding
Apr 21, 2026
Initiates: Buy
Price Target: $62
Current: $47.38
Upside: +30.86%
Ionis Pharmaceuticals
Apr 21, 2026
Initiates: Buy
Price Target: $110
Current: $72.52
Upside: +51.68%
Achieve Life Sciences
Apr 21, 2026
Initiates: Buy
Price Target: $13
Current: $4.77
Upside: +172.54%
Amgen
Apr 21, 2026
Initiates: Hold
Price Target: $366
Current: $324.39
Upside: +12.83%
Bausch + Lomb
Oct 30, 2025
Reiterates: Outperform
Price Target: $18 → $19
Current: $16.11
Upside: +17.94%
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $6.90
Upside: +624.64%
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $2.12
Upside: +843.40%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $12.05
Upside: +132.37%
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $286.27
Upside: +4.10%
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $22.44
Upside: +64.88%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $4.14
Upside: +69.29%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $229.55
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $11.92
Upside: -66.44%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $11.39
Upside: +163.39%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $4.16
Upside: +669.23%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $16.50
Upside: -15.15%
Nov 14, 2022
Maintains: Outperform
Price Target: $90 → $75
Current: $9.60
Upside: +681.25%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $34.03
Upside: -70.61%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $28.61
Upside: +4.86%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $4.73
Upside: +15,756.24%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $5.34
Upside: +49.81%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $17.20
Upside: +22.09%